Acorda Therapeutics presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson's Disease Rating Scale :
Summary of Data:
- CVT-301 Phase 3 SPAN-PD study met primary endpoint of improvement in UPDRS III, in data presented at 2017 International Congress of Parkinson's Disease and Movement Disorders.
- Multiple secondary endpoints were supportive of primary endpoint result
- Acorda plans to file New Drug Application (:NDA) in U.S. by end of Q2 2017
No comments:
Post a Comment